• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    QT Imaging Receives FDA Clearance for Its Breast Acoustic CT Scanner Enhanced Configuration to Improve Posterior Breast Imaging Coverage

    3/10/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $QTI alert in real time by email

    QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated configuration of its Breast Acoustic CT™ scanner, the Company's 3D ultrasound tomographic breast imaging system. The newly cleared enhanced configuration improves visualization and expands coverage of posterior breast tissue.

    "The updated configuration cleared by the FDA incorporates a tilted transmitter geometry that improves tomographic imaging coverage of breast tissue located near the chest wall, which is an area that can be extremely challenging to capture," said Bilal Malik, PhD, Chief Science Officer of QT Imaging. "This design delivers more complete coverage and improved overall diagnostic utility by optimizing the scanner's ability to include posterior breast tissue that is often difficult to image with standard approaches. We remain dedicated to developing and refining innovative technologies that provide greater precision and confidence to deliver the best outcomes for women regardless of breast density."

    The QTI Breast Acoustic CT scanner generates both reflection-mode and transmission-mode ultrasound data to reconstruct 3D tomographic images. Its proprietary software quantifies fibroglandular tissue volume (FGV) and the ratio of fibroglandular tissue to total breast volume (TBV), providing valuable insight for breast health assessment and monitoring.

    About QT Imaging

    QT Imaging Holdings, Inc. (NASDAQ:QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the Company's website at www.qtimaging.com.

    Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the QT Imaging Breast Acoustic CT™ Scanner, including its commercialization, manufacturing (including large scale) and further development, advanced image reconstruction software performance of software enhancements, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging's industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT™ Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and "bring to market" plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company's reports and other documents filed with the SEC, including under the heading "Risk Factors." If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging's expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging's assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260310679250/en/

    Investors

    Alliance Advisors IR

    Jody Cain

    [email protected]

    310-691-7107

    Media

    Alliance Advisors IR

    Fatema Bhabrawala

    [email protected]

    647-620-5002

    Get the next $QTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QT Imaging Receives FDA Clearance for Its Breast Acoustic CT Scanner Enhanced Configuration to Improve Posterior Breast Imaging Coverage

    QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated configuration of its Breast Acoustic CT™ scanner, the Company's 3D ultrasound tomographic breast imaging system. The newly cleared enhanced configuration improves visualization and expands coverage of posterior breast tissue. "The updated configuration cleared by the FDA incorporates a tilted transmitter geometry that improves tomographic imaging coverage of breast tissue located near the che

    3/10/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging Names Renowned Breast Cancer Researcher Dr. Mary Yamashita as Medical Advisor

    QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that Mary W. Yamashita, MD will serve as Medical Advisor to the Company. In her role as QT Imaging Medical Advisor, Dr. Yamashita will provide strategic advisory and development support across several key areas, including clinical interpretation standards, structured reporting frameworks, training architecture, and reader study design. Her expertise will be instrumental in optimizing clinical integration and user experience, ensuring that the Company's technologies not only

    3/4/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging Achieves Major Reimbursement Milestone with AMA Category III CPT Code for 3D Breast Ultrasound Tomography

    The Company's first CPT code becomes effective January 1, 2027, enables billing and opening new commercial opportunities with hospital accounts QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that the American Medical Association (AMA) CPT (Current Procedural Terminology) Editorial Panel has approved a new Category III CPTTM code for 3D quantitative transmission volumetric ultrasound tomography of the breast. The new Category III code, X579T, represents a significant milestone in the clinical and commercial advancement

    2/23/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Greene James S bought $250,000 worth of shares (428,082 units at $0.58) (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:04:44 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Dickson Daniel H bought $50,000 worth of shares (85,616 units at $0.58) (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:03:54 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chairman Katz Avi S bought $1,834,999 worth of shares (3,142,122 units at $0.58), increasing direct ownership by 252% to 657,960 units (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:03:30 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Greene James S bought $250,000 worth of shares (428,082 units at $0.58) (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:04:44 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Dickson Daniel H bought $50,000 worth of shares (85,616 units at $0.58) (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:03:54 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chairman Katz Avi S bought $1,834,999 worth of shares (3,142,122 units at $0.58), increasing direct ownership by 252% to 657,960 units (SEC Form 4)

    4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

    11/14/24 9:03:30 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    SEC Filings

    View All

    QT Imaging Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

    2/25/26 4:06:30 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

    2/18/26 8:41:05 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SCHEDULE 13G filed by QT Imaging Holdings Inc.

    SCHEDULE 13G - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)

    2/17/26 4:48:41 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Leadership Updates

    Live Leadership Updates

    View All

    QT Imaging Announces First Quarter 2024 Financial Results

    Generated Scanner Sales Revenue of $1.4M with 56% Gross Margin in the First Quarter of 2024, Since the Company Became Public on March 4th Streamlined Business Model via Strategic Sales and Distribution Partnership in USA Reported in Academic Radiology the Results of a Second Blinded Screening Trial That Found That QTI Technology Is Similarly Effective as Digital Breast Tomosynthesis (DBT) or 3D Mammography Company Completed Merger with GigCapital5 QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the first qu

    5/10/24 8:57:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by QT Imaging Holdings Inc.

    SC 13D/A - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)

    11/22/24 4:15:11 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by QT Imaging Holdings Inc.

    SC 13G - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)

    11/14/24 4:01:08 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by QT Imaging Holdings Inc.

    SC 13D/A - QT IMAGING HOLDINGS, INC. (0001844505) (Subject)

    9/13/24 4:23:43 PM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $QTI
    Financials

    Live finance-specific insights

    View All

    QT Imaging Reports Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Generated Record Revenue of $8.3 Million in Q4 2025, up 97% versus Q3 2025 Shipped Record 17 Scanners in Q4 2025 and 40 in 2025, up from 12 Scanners Shipped in 2024 Exceeded 2025 Sales Outlook, Delivering Revenue of $18.9 Million Relisted on Nasdaq Less Than One Year After Leaving the Exchange Continues to Pivot from a Scanner Company to a SaaS and Biomarker-Driven Medical Imaging Franchise QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company") a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announces preliminary unaudited financial results for the fourth quarter and full year

    2/18/26 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging Announces Third Quarter 2024 Financial Results

    Generated Scanner Sales Revenue of $0.9 Million with 65% Gross Margin in the Third Quarter of 2024 The Company Successfully Completed the Engineering and Clinical Feasibility Study with its Strategic Partner The Company Announced Entering into Favorable Amendments to Its $10 Million Convertible Promissory Note with YA II PN, Ltd. The Company Announced Insiders PIPE investment of $2.56 Million, fully funded by the QTI Board of Directors members and their Affiliates QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results

    11/13/24 8:32:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    QT Imaging Announces Second Quarter 2024 Financial Results

    Generated Scanner Sales Revenue of $1.7 Million with 51% Gross Margin in the Second Quarter of 2024 The Company Continues to Make Progress in the Engineering and Clinical Feasibility Study with its Strategic Partner Signed a U.S. Exclusive Distribution Agreement Announced Partnership with the University of Oklahoma and OU Health Stephenson Cancer Center to Improve Precision in Cancer Detection and Treatment QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the second quarter of 2024. "QT Imaging's team comp

    8/8/24 8:30:00 AM ET
    $QTI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care